The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects

@article{Feldman2013TheCO,
  title={The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects},
  author={Gregory J Feldman and Anton Edin},
  journal={Therapeutic Advances in Respiratory Disease},
  year={2013},
  volume={7},
  pages={311 - 319}
}
  • G. FeldmanA. Edin
  • Published 3 September 2013
  • Medicine
  • Therapeutic Advances in Respiratory Disease
The defining feature of chronic obstructive pulmonary disease (COPD) is progressive airflow limitation that causes air trapping and hyperinflation. The increasing hyperinflation results in dyspnea along with associated inability to engage in the activities of daily living. The American Thoracic Society (ATS), European Respiratory Society (ERS) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) treatment guidelines all place bronchodilators as the foundation of pharmacological… 

Figures and Tables from this paper

Umeclidinium/Vilanterol: A Review of Its Use as Maintenance Therapy in Adults with Chronic Obstructive Pulmonary Disease

Inhaled umeclidinium/vilanterol extends the treatment options currently available for the maintenance treatment of adults with COPD and has the convenience of once-daily administration.

Tiotropium Bromide/Olodaterol as Maintenance Treatment for Patients with COPD

Overall, tiotropium plus olodaterol FDC should be considered as an option for maintenance therapy in patients with moderately severe and severe COPD, and further studies will be required to show the effectiveness.

Considerations for new dual-acting bronchodilator treatments for chronic obstructive pulmonary disease

Two closely related approaches to provide long-acting treatments are compared: the LABA/LAMA fixed-dose combination therapy, and the dual-acting muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA).

Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD – role of umeclidinium/vilanterol

Data from large clinical trials involving more than 4,500 COPD patients indicate that UMEC/VI is an effective once-daily treatment in COPD with improved pulmonary function.

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent.

Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment

ACL/FF 400/12 µg was a cost-saving therapy in patients with moderate-to-severe COPD in Spain, and provided equivalent effects compared to TIO/OLO 5/5 g.

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease

This article reviews both clinically approved ULABA’s and ULABAs in development and describes how these agents are being combined with antimuscarinic agents and corticosteroids as dual and triple agent treatments that are being tested for clinical use and efficacy.

Discovering the Relative Efficacy of Inhaled Medications for Chronic Obstructive Pulmonary Disease: Multiple Treatment Comparisons

The combined inhaled medication of ICS + LABA + LAMA may be more efficacious than other inhaled medications for COPD patients.

Tailoring of corticosteroids in COPD management

This literature review updates the reader on the new studies regarding steroid therapy over the last year in stable COPD and in exacerbations, and reports the REDUCE trial findings favouring a 5-day course of systemic steroids, and other trials addressing which steroid and route to use, including in an intensive care setting.

References

SHOWING 1-10 OF 42 REFERENCES

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

The existing data for LAMA/LABA combinations in the treatment of COPD is outlined, the ongoing trials are summarized, and the evidence required to inform the role of LAMA-LABA combination in treatment of this disease is considered.

Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes.

Raising awareness of the importance of outcomes beyond lung function alone, particularly in primary care where most patients initially present themselves for medical evaluation, should form a fundamental part of a more holistic approach to COPD management.

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

In the treatment of COPD, there is benefit from adding formoterol once or twice daily to tiotropium once daily in terms of improvement in airflow obstruction, resting hyperinflation, and the use of rescue salbutamol.

Combination of Formoterol and Tiotropium in the Treatment of COPD: Effects on Lung Function

A combination of tiotropium and formoterol is more effective than single drugs alone in inducing bronchodilation and aBronchodilator-mediated symptom benefit in patients suffering from COPD.

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison

Indacaterol plus tiotropium provided greater bronchodilation and lung deflation (reflected by increased resting IC) and support COPD guideline recommendations to combine Bronchodilators with different mechanisms of action.

Indacaterol: a new once daily long-acting beta2 adrenoceptor agonist

Preclinical and clinical data of indacaterol are summarized, including all data generated during the phase II trial program, and the outlook and potential of the drug in the future treatment of COPD and asthma are discussed.

Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients

The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD.

The study suggests that the addition of tiotropium to ICSs and LABA therapy may confer benefits in reducing all-cause mortality, hospital admissions, and oral corticosteroid bursts in patients with COPD.